Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Butyrolactone. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthesis route for gamma-butyrolactone dimer anticancer compounds offers high purity and scalable manufacturing for pharmaceutical intermediates supply chains.
Patent CN112759566B details a safer, high-yield (>96%) synthesis of ABL using liquid sodium methoxide, offering significant supply chain and cost advantages for pharmaceutical manufacturers.
Patent CN100503590C details a novel Rh-catalyzed hydrogenation of L-malic acid diester. This method offers high optical purity and lower pressure conditions for efficient API intermediate manufacturing.
Patent CN103387556A details a safer synthetic route for alpha-acetyl-gamma-butyrolactone, eliminating hazardous reagents while achieving yields over 85%.
Patent CN111635437B reveals a novel palladium catalyst enabling mild, one-pot synthesis of alpha-methylene-gamma-butyrolactones, offering significant cost reduction in fine chemical manufacturing.
Novel copper-catalyzed [3+2] cycloaddition for high-purity alpha-amino-gamma-butyrolactones. Offers cost reduction in pharma intermediate manufacturing with scalable protocols.
Novel acid-catalyzed route offers high yield and cost efficiency for pharmaceutical intermediates manufacturing without precious metals.
Novel Pd/Cu-catalyzed cyclization of unactivated alkenes enables cost-effective production of bioactive lactones. Reliable supply chain partner for pharmaceutical intermediates.
Advanced synthesis of alpha-acetyl-gamma-butyrolactone via optimized Claisen condensation. Delivers 99.5% purity for Vitamin B1 and agrochemical manufacturing with reduced costs.
Novel Pd-catalyzed route for alpha-methylene-gamma-butyrolactone derivatives. Mild conditions, high functional group tolerance, scalable supply chain solutions for global pharmaceutical manufacturing partners.
Novel Bacillus megaterium strain enables high-purity R-4-chloro-3-hydroxybutyrate production with reduced costs and environmental impact.
Patent CN111393394B reveals a novel cobalt-catalyzed carbonylation of oxetanes. This method offers significant cost reduction in API manufacturing through mild conditions and base metal catalysis.
Patent CN115073399A reveals a low-cost bifunctional catalyst for high-yield chiral beta-butyrolactone production, offering significant supply chain advantages.
Patent CN109553595A reveals mild chiral gamma-butyrolactone synthesis. Reduces cost and improves supply chain reliability for pharmaceutical intermediates.
Novel synthesis of anti-tumor intermediates offering high purity and scalable production for pharmaceutical manufacturing supply chains.
Patent CN104693162B reveals mild Cu-catalyzed route. Enhances supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN101768141B reveals solvent-free sodium catalysis for alpha-acetyl-gamma-butyrolactone. Enhances safety, purity, and cost efficiency for pharmaceutical intermediate manufacturing supply chains.
Novel aqueous method for alpha-amino-gamma-butyrolactone production improves yield over conventional routes. Ideal for reliable pharma intermediate supply chains and cost-effective manufacturing.
Patent CN104250236B details a one-pot CuH method for lactones, offering cost reduction in pharma intermediate manufacturing and high purity.
Novel green synthesis route for DL-alpha-hydroxy-beta,beta-dimethyl-gamma-butyrolactone offering high yield and purity for vitamin B5 manufacturing supply chains.